The Best of Reason: Can This Psychedelic Help Cure Opioid Addiction?
This Kentucky Republican won't stop until he finds a state willing to make legal room for ibogaine, a drug he calls "God's medicine."
This Kentucky Republican won't stop until he finds a state willing to make legal room for ibogaine, a drug he calls "God's medicine."
This Kentucky Republican won't stop until he finds a state willing to make legal room for ibogaine, a drug he calls "God's medicine."
An FDA advisory committee concluded that MDMA's benefits had not been shown to outweigh its risks.
The FDA, which approved the protocols for the studies it now questions, is asking for an additional Phase 3 clinical trial, which would take years and millions of dollars.
The panel's recommendation, based on several concerns about two clinical trials, is a serious setback for a promising PTSD treatment.
Not only won’t they blow your mind, but they may even save it (sometimes legally).
Subjects diagnosed with severe post-traumatic stress disorder made substantially more progress when they received MDMA rather than a placebo.
Rick Doblin, a leading force in America's psychedelic renaissance, imagines a world of "mass mental health" facilitated by formerly demonized drugs.
The Multidisciplinary Association for Psychedelic Studies (MAPS) is making MDMA and other drugs medically legitimate and socially acceptable.
Phillip Brailsford was acquitted of murder for a shooting captured on video that subsequently drew national outrage. Now he's getting paid for it.
"I think it’s ridiculous I would have to trade one of my rights," said veteran Joshua Raines.
MDMA, which was banned by the Drug Enforcement Administration in 1985, could be available by prescription as soon as 2021.
Banned Since 1985, MDMA could soon be approved as a PTSD treatment.
But they're still forbidden from recommending or prescribing, and the government won't pay for it.
Veterans turn to forbidden cures for relief from their nightmares.
Do you care about free minds and free markets? Sign up to get the biggest stories from Reason in your inbox every afternoon.
This modal will close in 10